Marinus (MRNS) Gets a Buy Rating from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Marinus (MRNSResearch Report), with a price target of $38.00. The company’s shares closed last Tuesday at $13.80.

According to, Tsao is a 5-star analyst with an average return of 15.3% and a 51.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

Marinus has an analyst consensus of Strong Buy, with a price target consensus of $34.00.

See today’s analyst top recommended stocks >>

Based on Marinus’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.81 million and GAAP net loss of $27.14 million. In comparison, last year the company had a GAAP net loss of $18.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.